《柳叶刀呼吸医学2025》修正；13: e39-40

IF 32.8 1区医学 Q1 CRITICAL CARE MEDICINE

Lancet Respiratory Medicine Pub Date : 2025-07-29 DOI:10.1016/s2213-2600(25)00261-9

{"title":"《柳叶刀呼吸医学2025》修正；13: e39-40","authors":"","doi":"10.1016/s2213-2600(25)00261-9","DOIUrl":null,"url":null,"abstract":"Venkatesan P. The carbon footprint of inhaled medications in Australia. Lancet Respir Med 2025; 13: e39–40—In this News piece, in the second paragraph, the third and fourth sentence should read “a position paper by Wurzel and colleagues highlights that hydrofluorocarbons (HFCs) in pressurised metered dose inhalers (pMDIs) are estimated to be responsible for 13% of the UK National Health Service carbon dioxide equivalent (CO2e) emissions related to the delivery of care and 3% of total health sector emissions.” This correction has been made as of July 29, 2025.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"52 1","pages":""},"PeriodicalIF":32.8000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Respir Med 2025; 13: e39–40\",\"authors\":\"\",\"doi\":\"10.1016/s2213-2600(25)00261-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Venkatesan P. The carbon footprint of inhaled medications in Australia. Lancet Respir Med 2025; 13: e39–40—In this News piece, in the second paragraph, the third and fourth sentence should read “a position paper by Wurzel and colleagues highlights that hydrofluorocarbons (HFCs) in pressurised metered dose inhalers (pMDIs) are estimated to be responsible for 13% of the UK National Health Service carbon dioxide equivalent (CO2e) emissions related to the delivery of care and 3% of total health sector emissions.” This correction has been made as of July 29, 2025.\",\"PeriodicalId\":51307,\"journal\":{\"name\":\"Lancet Respiratory Medicine\",\"volume\":\"52 1\",\"pages\":\"\"},\"PeriodicalIF\":32.8000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2213-2600(25)00261-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00261-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

澳大利亚吸入药物的碳足迹。柳叶刀呼吸医学2025；[13:39 - 40]在这篇新闻报道的第二段中，第三和第四句应该是“Wurzel及其同事的一份立场文件强调，据估计，与提供医疗服务有关的英国国民健康服务二氧化碳当量（CO2e）排放量中，有13%是由加压计量吸入器（pmdi）中的氢氟碳化物（HFCs）造成的，占卫生部门总排放量的3%。”此更正已于2025年7月29日进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Respir Med 2025; 13: e39–40

Venkatesan P. The carbon footprint of inhaled medications in Australia. Lancet Respir Med 2025; 13: e39–40—In this News piece, in the second paragraph, the third and fourth sentence should read “a position paper by Wurzel and colleagues highlights that hydrofluorocarbons (HFCs) in pressurised metered dose inhalers (pMDIs) are estimated to be responsible for 13% of the UK National Health Service carbon dioxide equivalent (CO₂e) emissions related to the delivery of care and 3% of total health sector emissions.” This correction has been made as of July 29, 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM

CiteScore

87.10

自引率

0.70%

发文量

572

期刊介绍： The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.